Skip to Main Content

Paper Details

Targeting mTOR signaling overcomes acquired resistance to combined BRAF and MEK inhibition in BRAF-mutant melanoma.
Oncogene
26
2021
AKT, BRAF, BRAF-mutant, BRAF-mutant melanoma, BRAFi, CR, CR cell lines, CR cells, CR melanoma, CR melanoma cells, CR xenograft models, ERK, MAPK, MEK, MEKi, NVP-BEZ235, PTEN, cultured cells, mTOR, mTORC1, melanoma, rapamycin, tumor, tumors
Author NameAffiliation
Gao ZhangMolecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute
Gao ZhangDuke University Medical Center
Lawrence N KwongUniversity of Texas MD Anderson Cancer Center
Jie ZhangNew Jersey Institute of Technology
Zhi WeiNew Jersey Institute of Technology
Yiling LuThe University of Texas MD Anderson Cancer Center
Gordon B Millsand Knight Cancer Institute, Oregon Health & Science University
Gordon B Millsand Knight Cancer Institute, Oregon Health & Science University
Meenhard HerlynMolecular and Cellular Oncogenesis Program and Melanoma Research Center, The Wistar Institute
  • 1 - 9

Datasets

Release 1.2